



# AKI in dogs and cats: Update on diagnosis and treatment.

Bill Saxon, DVM, DACVIM, DACVECC  
IDEXX Medical Education Specialist

**IDEXX**


# CKD: progressive, irreversible, no return to normal function

- Persistent ( $\approx$  >3 month) abnormality in 1 or more kidney function or structure
  - Azotemia (overt or progressive increase in creat or SDMA within ref interval)
  - Persistent SDMA >14 ug/dL precedes increase in creatinine
  - Persistent renal proteinuria
  - Persistent USG <1.030 dog, <1.035 cat with nonrenal cause excluded
  - Tubular dysfunction, e.g., normoglycemic glucosuria, granular casts, cystatin B
  - Structural abnormality, e.g., small, irregular kidneys, cysts...
- Single abnormality common
  - Proteinuria without azotemia or decreased USG
  - Decreased USG without increased creatinine
- **Prerenal or postrenal factors excluded**
- **Rate of progression variable and hard to predict**


# AKI: potentially reversible, kidney function *may* return to normal

- Abrupt decline in kidney function
- Prerenal, renal, postrenal causes
- Earliest evidence found in urine
- Azotemia not always present initially
- AKI may be present on presentation or develop in hospital (unstable patients)
- May lead to CKD

# Back in the day...




# Today...



# Today...

Your AKI patient may have or develop CKD.



Your CKD patient may have concurrent active kidney injury.

# Practically speaking:

- AKI and CKD might not be separate processes
- One may be predominant at presentation
  - Stable CKD patient on treatment in for monitoring visit...
  - Crashing emergency patient with marked azotemia...
- Important to remember
  - Both may be present on presentation
  - One may lead to the other
- Key to new understanding
  - CKD can have active injury component which may lead to faster progression
  - AKI – severe, sustained, intermittent – can lead to CKD
  - Inflammation is likely unifying abnormality...

# Causes of AKI: may develop in hospital

## Cat

- Obstruction (ureteral, urethral)
- *Lilium spp.* ingestion
- Diuretics (congestive heart failure)
- NSAIDs
- Chemotherapeutics
- Pyelonephritis
- Acute pancreatitis
  
- Etiology unknown 30%

## Dog

- Leptospirosis
- NSAIDs
- Sepsis
- Lyme nephritis
- Grapes/raisin ingestion
- Chemotherapeutics/antifungals
- Aminoglycosides
- Acute pancreatitis
- Congestive heart failure



# Rule out ureteral obstruction in cats with AKI

Renal pelvic dilation  $>13$  mm rules in obstruction

No or minimal dilation does not rule out obstruction

$<3.4$  mm on IV fluids acceptable

Serial ultrasound

# AKI risk factors: monitor these patients closely.

Prerenal, renal, postrenal causes.

- Dehydration
- Age – very young or old
- Diuretic or nephrotoxic drug therapy
- Hypokalemia or hypercalcemia
- Sepsis
- Congestive heart failure
- Acute pancreatitis
- Systemic hypertension
- CKD

# IRIS AKI grading system

Creatinine increase  $\geq 0.3$  mg/dl in 48h  
(Or increase 1.5x baseline in 7d)

Urine production  $<1$  ml/kg/h over 6h

- Laboratory evidence of *nonazotemic* AKI
  - SDMA increased
  - Urinary casts, glucosuria with normoglycemia
  - Urine cystatin B

## AKI dynamic

Improve, worsen, progress to CKD  
Apply grading scheme daily or more often

**Table 1: IRIS AKI Grading Criteria**

AKI Grade	Blood Creatinine	Clinical Description
<b>Grade I</b>	$<1.6$ mg/dl ( $<140$ $\mu$ mol/l)	Nonazotemic AKI: a. Documented AKI: (historical, clinical, laboratory, or imaging evidence of AKI, clinical oliguria/anuria, volume responsiveness $\ddagger$ ) and/or b. Progressive nonazotemic increase in blood creatinine: $\geq 0.3$ mg/dl ( $\geq 26.4$ $\mu$ mol/l) within 48 h c. Measured oliguria ( $<1$ ml/kg/h)# or anuria over 6 h
<b>Grade II</b>	$1.7 - 2.5$ mg/dl ( $141 - 220$ $\mu$ mol/l)	Mild AKI: a. Documented AKI and static or progressive azotemia b. Progressive azotemic: increase in blood creatinine; $\geq 0.3$ mg/dl ( $\geq 26.4$ $\mu$ mol/l) within 48 h), or volume responsiveness $\ddagger$ c. Measured oliguria ( $<1$ ml/kg/h)# or anuria over 6 h
<b>Grade III</b>	$2.6 - 5.0$ mg/dl ( $221 - 439$ $\mu$ mol/l)	
<b>Grade IV</b>	$5.1 - 10.0$ mg/dl ( $440 - 880$ $\mu$ mol/l)	Moderate to Severe AKI: a. Documented AKI and increasing severities of azotemia and functional renal failure
<b>Grade V</b>	$>10.0$ mg/dl ( $>880$ $\mu$ mol/l)	

	Day 1	Day 2	Day 3	Day 4	Day 5
<b>Patient 1</b>	0.9	1.5	1.5	1.5	1.7
<b>Patient 2</b>	2.3 CKD	2.5 CKD	2.7	3.5	2.4
<b>Patient 3</b>	5.3	5.2	3.6	2.4	1.6
<b>Patient 4</b>	4.8	5.8	6.9	10.8	RRT
<b>Patient 5</b>	18.2	RRT	RRT	RRT	RRT

● Non AKI  
 ● AKI Grade I  
 ● AKI Grade II  
 ● AKI Grade III  
 ● AKI Grade IV  
 ● AKI Grade V



## Education

[IRIS Staging System](#)

[Risk Factors for CKD](#)

# Differentiation between Acute kidney injury and chronic kidney disease (updated 2022)

Gilad Segev, Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Israel

# Hallmarks of AKI (vs CKD)

- History and physical exam
  - Acute onset – hours to days
  - Toxin exposure (lily, NSAIDs, anesthetics...)
  - Renomegaly, renal pain
  - Bradycardia/hypothermia (hyperkalemia)
- Lab findings
  - Hyperkalemia
  - Urinalysis abnormalities differ
- Imaging
  - Renomegaly in 70%
  - Hydroureter, pyelectasia, hydronephrosis
  - Ureteral calculi
  - Normal parathyroid gland

# Traditional and **newer** markers to assess kidneys

## Functional markers (serum)

BUN

CREA (70-75% function loss before increase)

SDMA (30-40% function loss before increase)

**FGF-23 maybe someday**

Often normal w/in 1<sup>st</sup> 48 h of acute injury

## Injury markers (urine)

Granular casts

Renal epithelial cells

Proteinuria

Normoglycemic glucosuria

**Cystatin B now**

Detect subclinical kidney injury before ↓ GFR

# Hot Topic: active injury biomarkers.


- Presence in URINE sensitive predictor of acute or sustained renal tubular cell injury
- Released from stressed, damaged, ruptured kidney cells
- Epithelial damage present in AKI precedes increase in functional markers
  - SDMA, creatinine often normal first 48 hr
- Degree of epithelial damage associated with disease progression and survival

*“...IRIS encourages more studies to be initiated and ultimately published in peer-reviewed journals to provide the evidence for their use in clinical practice.”*




# AKI: earliest evidence in URINE.

- Proteinuria
- Hematuria
- Pyuria
- Bacteriuria
- Renal epithelial cells
- Glucosuria (normoglycemia)
- + Urine culture
- Granular casts  $\approx 16\%$
- Decreased urine production
- Decreased USG



# Urine Cystatin B detects *active* kidney tubular damage

(ALT of the kidney)



Harjen HJ, Anfinson KP, Hultman J, et al. Evaluation of urinary clusterin and cystatin B as biomarkers for renal injury in dogs envenomated by the European adder (*Vipera berus*). *Top Companion Anim Med.* 2022;46:100586. doi:10.1016/J.TCAM.2021.100586

Strybrat D, Jepson R, Bristow P, et al. Prospective evaluation of novel biomarkers of acute kidney injury in dogs following cardiac surgery under cardiopulmonary bypass. *J Vet Emerg Crit Care.* 2022; 32(6):733-742. doi:10.1111/VEC.13250

# Consider Cystatin B with:

- AKI
  - Confirm active injury following toxin exposure
  - Monitor treatment and recovery from acute injury event
  - Monitor high risk patient on NSAIDs
  - Monitor kidneys during shock, heat stroke, pancreatitis, envenomation...
- CKD
  - Predict progression of Stage 1 CKD in dogs
  - Identify early CKD (?)
- Others...??



# AKI treatment:

- Stabilize
- Correct life-threatening hyperkalemia
- Specific treatment if cause identified
- Manage oliguria/anuria
- Monitor for development of CKD

Fluids are a drug – avoid overdose.

# Rethinking fluid therapy for kidney disease

- Fluids do not improve kidney function
  - May increase urine *volume*
- Excess more likely to cause harm than improve kidney function
  - Endothelial glycocalyx degradation
  - Interstitial edema
- Forced diuresis is over
  
- Apply basic principles
  - Correct dehydration
  - Restore volume
  - Replace ongoing losses, e.g., vomiting, diarrhea...
  - Provide maintenance until eating and drinking normally



# IV fluids for AKI

- Avoid excess fluid
  - Decreased GFR and RBF due to increased renal interstitial pressure
  - Tissue hypoxia due to impaired O<sub>2</sub> diffusion
- Aim for euvolemia and euhydration
  - CRT, membranes, HR, pulses, mentation, lactate, base excess = perfusion parameters
- Balanced crystalloid with calcium
  - LR's, Hartmann's
  - Normosol-R, Plasma-Lyte 148 no Ca, acetate vasodilatory (?)
- Not 0.9% NaCl even if hyperkalemia
  - Acidifying
  - Afferent arteriolar constriction



# IV fluids for AKI, cont'd.

- Correct dehydration in 4-6 hr
  - $\text{Body weight (kg)} \times \text{estimated \% dehydration} \times 1000 = \text{fluid deficit in milliliters}$
- Provide maintenance and keep up with ongoing losses
  - 44-66 ml/kg/d
- Switch to lower sodium fluid for longer maintenance therapy
  - LR half-strength with 2.5% dextrose, 0.45% NaCl in 2.5% dextrose
  - Home made: 1:1 dilution of LR and 0.5% dextrose
- Monitor body weight
  - Know baseline, precise scale, take into account IV catheters, bandages, e collars, etc.
  - 5% BW gain minimum threshold for clinical signs (chemosis, mild interstitial edema, regurgitation)
  - 10% BW gain pulmonary edema, body cavity effusion

# IV fluids after nephrotoxin exposure: help or hurt?

- NSAIDs, lily (cat), grapes (dog)
- Fluids at 2-3x maintenance 2-3 d to induce diuresis standard recommendation
  - No evidence that increases toxin excretion or prevents tubular damage
  - Increases ANP which can degrade EG
  - Kidney interstitial edema → ↑ intraparenchymal pressure (rigid capsule) – ↓ perfusion/GFR
- Excessive fluid may *contribute* to AKI rather than prevent it.
- No mandatory hospitalization for IV fluids
- Use basic principles
  - Correct dehydration/hypovolemia, replace losses from V/D, maintenance if inappetence
  - Discharge when eating and drinking normally w/o excessive losses

# Treat life-threatening hyperkalemia

- Hypothermia *and* bradycardia indications to treat
- 10% calcium gluconate
  - Cardioprotective, buys time
  - 0.5-1.5 ml/kg over 10-15 minutes
- Regular insulin and 50% dextrose
  - $\frac{1}{4}$  U/kg with 2 gm 50% dextrose/U of insulin
- HCO<sub>3</sub> rarely necessary
  - Consider if pH < 7.1, HCO<sub>3</sub> < 12 mmol/L
  - $BW \text{ (kg)} \times 0.3 \times (24 - HCO_3) = \text{mEq HCO}_3 \text{ deficit}$
  - Give  $\frac{1}{2}$  deficit IV over 30 minutes
  - If pH not > 7.2 remainder in IV fluids over 2-4 hr

# Assume all inappetent cats are 5% dehydrated...and correct

Estimated dehydration	Physical examination reveals:
<5%	Not detectable
5-6%	Dry, 'tacky' mucous membranes
6-8%	Mild decrease skin turgor
8-10%	Obvious decrease skin turgor, retracted globes
10-12%	Persistent skin tenting, dull corneas, hypovolemia
>12%	Death due to hypovolemic shock

Formula: % dehydration as decimal x BW (kg) x 1000 = ml to administer over 4-24 hr

e.g., 5% dehydrated, 5 kg cat  
 $0.05 \times 5 = 0.25 \text{ L} \times 1000 = 250 \text{ ml}$ .

If azotemia worsens on IV fluids consider *decreasing* fluid rate.

Especially if total daily volume exceeds maintenance or if weight gain.

STOP fluids, +/- Lasix 1-4 mg/kg IV

# Detect oliguria and anuria

- Measuring urine output **important** yet often neglected
- Indwelling urinary catheter and closed aseptic collection system optimal
  - Collection bag below patient
  - Daily disinfection of ports, visible portion of catheter, prepuce, etc.
  - Change q2-3 days
- Estimate using absorbent pads when catheterization not possible
  - Weigh before and after use
  - 1 gm = 1 ml
- Oliguria <0.5-1.0 ml/kg/hr
  - AFTER hydration and volume restored (physiologic oliguria)
  - Consider if urine production does not increase after rehydration to 2-5 ml/kg/h
  - Ensure collection system connected, patent

# Treating oliguria/anuria simplified

- Furosemide - most effective route
  - Loading dose 0.66 mg/kg IV then CRI at 0.66 mg/kg/h (0.5-1.0 mg/kg/h)
- Furosemide - simplest route
  - 2 mg/kg IV initially
    - If no urine production within 20-40 minutes
  - 4 then 6 mg/kg IV hourly
  - Effective dose q6-8 h
- Mannitol, dopamine, fenoldopam no
- If no increase in urine production ins and outs +/- renal replacement therapy

# Ins and outs for oliguria/anuria

- Never in dehydrated or hypovolemic pets
- Match fluids exactly with urine produced to avoid fluid overload
- Total fluids to administer (and not a drop more) =  
    Insensible loss (respiration, feces) 22 ml/kg/d +  
    Sensible loss (urine) +  
    Ongoing loss (vomiting, diarrhea)
- Given in 4 or 6 hr intervals



In and outs for 5 kg cat, normal hydration, no v/d

Fluids are given in 6 h increments

Insensible loss  $20 \text{ ml/kg/d} \div 4 = 5 \text{ ml/kg} \times 5 \text{ kg} = 25 \text{ ml}$

Urine production = 0 ml

No v/d = 0 ml

25 ml total volume to administer over next 6 h = 4-5 ml/h

6 hours later...

Urine produced in preceding 6 h = 20 ml

Vomitus = 10 ml

Insensible loss in 6 h = 25 ml

55 ml total volume to administer over next 6 h = 9-10 ml/h

Repeat calculation every 6 hours until urine production  $> 1$  ml/kg/h

# Fluid therapy during recovery phase

- Polyuria may be profound
- Especially with obstructive disease or leptospirosis (dogs)
- Higher fluid rates than any other disease
- Hypokalemia may result – add KCl to fluids
- Monitor urine volume, BW, perfusion, hydration parameters and keep up!
- Taper 10-25% per day once stable and continue reassessing

# Adjusting drug dosages and/or frequency with AKI

- Important if drug excreted by kidneys
- Interval (hr) = normal interval (h) x serum creatinine
- Dose = normal dose / serum creatinine

# Prognosis

- Mortality 58-73%
- Better outcomes with infectious causes
- Degree of azotemia not associated with outcome
- Poor prognostic indicators
  - Decreased urine production
  - Hypothermia
  - Hyperkalemia
  - Hypoalbuminemia
  - Decreased HCO<sub>3</sub> at admission
- Kidney dysfunction that lasts >3 months after AKI = CKD

# Key Takeaways

- AKI can be present on admission or develop in the hospital
- AKI predisposes to CKD and vice versa
- Daily grading using IRIS AKI guidelines is indicated in unstable patients
- Earliest indicators of AKI are in urine
- Azotemia not always present with AKI
- Urine cystatin B is a sensitive marker of kidney tubule damage
- Monitoring body weight and urine output is critical
- Hypervolemia can cause or exacerbate AKI
- Prognosis is generally guarded but better with infectious causes and early appropriate therapy

Thank you!